内皮祖细胞在肿瘤临床诊断与治疗中应用的研究进展

Progress in endothelial progenitor cells in tumor diagnosis and treatment

内皮祖细胞作为血管内皮细胞的前体细胞,具有高度增殖和定向分化成血管内皮细胞的能力。肿瘤的生长、侵袭和转移均高度依赖于血管,而内皮祖细胞在肿瘤临床诊断和治疗中的应用已取得明显进展。通过内皮祖细胞干扰和阻滞血管新生可以抑制卵巢癌、前列腺癌和乳腺癌等肿瘤的生长,内皮祖细胞亦可能作为基因载体应用于肿瘤基因治疗,而且内皮祖细胞有可能作为一种新的生物标志物用于肾细胞癌、非霍奇金淋巴瘤和乳腺癌的诊断、分型、分期及疗效评估。

Endothelial progenitor cells （EPC） have the capacity of high proliferation and directional differentiation into endothelial cells. Tumor cell growth, invasion and metastasis are highly dependent on the blood vessels. Thus, EPC ap- plication gets a significant progress in tumor diagnosis and treatment. Interference and blocking angiogenesis by EPC can inhibit the growth of ovarian cancer, prostate cancer and breast tumor. EPC may also be used as gene vectors in cancer gene therapy. And EPC may be used as a new biomarker in diagnosis, classification, staging and efficacy evaluation for renal cell carcinoma, non-Hodgkin lymphoma and breast cancer.